EC approves product for von Willebrand disease

US version of vonicog alfa
Photo from Shire
The European Commission (EC) has granted marketing authorization for vonicog alfa (Veyvondi), a recombinant von Willebrand factor (rVWF) product. The EC approved vonicog alfa for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease (VWD) when desmopressin treatment alone is ineffective or not indicated. The approval means Shire is authorized to market vonicog alfa in the European Union as well as in Iceland, Lichtenstein, and Norway. [Read Article]

Insights could change treatment, classification of MPAL

From left to right: Study
authors Ilaria Iacobucci,
Charles Mullighan, Hiroto
Inaba, and Zhaohui Gu
Photo from St. Jude
Children’s Research Hospital
An extensive analysis of mixed phenotype acute leukemia (MPAL) has led to new insights that may have implications for disease classification and treatment. Researchers believe they have identified new subtypes of MPAL that should be included in the World Health Organization (WHO) classification for acute leukemia. Each of these subtypes shares genomic characteristics with other acute leukemias, which suggests the new subtypes might respond to treatments that are already in use. [Read Article]

New U.S. cancer cases may exceed 2.3 million by 2035

Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report, detailing recent advances in the fight against cancer and calling on elected officials to address the challenges that remain. The AACR Cancer Progress Report 2018 lists the 22 new approvals for cancer treatments that have occurred during the last 12 months, including 12 therapies approved to treat hematologic malignancies. [Read Article]